GOLDEN, Colo. — Dec. 19, 2017 — PharmaJet, the maker of innovative, needle-free injection technology, announced that Invectys, a French-based biopharmaceutical company, received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system.
Invectys previously announced the success of the phase I clinical trial of their INVAC-1, an immunotherapeutic DNA vaccine for the treatment of cancer. The company has performed studies to evaluate the PharmaJet Tropis® Needle-free injection system, both in human and animal clinical trials with no evidence of any safety concerns. “We believe the PharmaJet Needle-free device offers many advantages to patients and providers including less pain and stress, elimination of needles and provides a more precise and consistent method for vaccine delivery,” said Pierre Langlade Demoyen, CEO of Invectys.
Cancer is a major public health issue and the leading cause of death worldwide, with approximately 14 million new cases and 8 million cancer-related deaths per year. Over 25 million people are living with cancer globally. (1) The global cancer burden is expected to exceed 20 million new cancer cases and more than 13 million deaths annually by 2025.
“We are pleased that the PharmaJet Tropis Intradermal device has been chosen as the method of administration for this important cancer immunotherapy vaccine development. The Needle-free device is safe, fast and easy to administer, and has already been used successfully in numerous clinical studies for nucleic acid (DNA or RNA) vaccine delivery,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 World Cancer Report 2014. World Health Organization. International Agency for Research on Cancer. Edited by Bernard W. Stewart and Christopher P. Wild.